AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage ResultsMarketBeat • Thursday
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • Monday
AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026Business Wire • 11/05/26
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual MeetingBusiness Wire • 10/08/26
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026Business Wire • 09/16/26
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026Business Wire • 09/02/26
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded WarrantsBusiness Wire • 08/13/26
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 08/11/26
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes TranscriptSeeking Alpha • 08/10/26
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability ProfileBusiness Wire • 08/10/26
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026Business Wire • 08/07/26